AI Is Accelerating Drug Development. Are the Commercial Agreements Keeping Up?

AI is changing pharmaceutical research and drug development, bringing new questions about intellectual property, licensing, milestone payments, and commercialization. As pharmaceutical companies partner with AI developers, their agreements must address who owns discoveries, how financial returns are divided, and what happens when compounds advance into clinical trials.